Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Purpose Galunisertib, a TGF-β inhibitor, has demonstrated antitumor effects in preclinical and radiographic responses in some patients with malignant glioma. This Phase 1b/2a trial investigated the clinical benefit of combining galunisertib with temozolomide-based radiochemotherapy (TMZ/RTX) in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wick, Antje, Desjardins, Annick, Suarez, Cristina, Forsyth, Peter, Gueorguieva, Ivelina, Burkholder, Tiana, Cleverly, Ann Louise, Estrem, Shawn T., Wang, Shuaicheng, Lahn, Michael M., Guba, Susan C., Capper, David, Rodon, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497674/
https://www.ncbi.nlm.nih.gov/pubmed/32140889
http://dx.doi.org/10.1007/s10637-020-00910-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497674/
https://www.ncbi.nlm.nih.gov/pubmed/32140889
http://dx.doi.org/10.1007/s10637-020-00910-9

Ejemplares similares